Scarica l'app Stockscreener
25.82
22.14%
4.68
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Looking At The Narrative For Roivant Sciences ROIV After 2026 Catalyst And Litigation Shifts - Yahoo Finance
Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? - Benzinga
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026 - MSN
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative - simplywall.st
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress - Finviz
Roivant Sciences earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
10 Easy Double-Digit Gainers - Insider Monkey
Roivant Sciences Q3 2026 Earnings Call Transcript - MarketBeat
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum - Investing.com Nigeria
Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss - simplywall.st
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge - Investing.com Nigeria
Why Is Roivant Stock Trading Higher Today?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences Q3 Earnings Call Highlights - Yahoo Finance
Immunovant Q3 Earnings Call Highlights - Yahoo Finance
ROIV: Strong phase II data for brepocitinib in cutaneous sarcoidosis; multiple pivotal readouts ahead - TradingView
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum By Investing.com - Investing.com South Africa
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib - Nasdaq
Roivant Sciences stock soars after positive cutaneous sarcoidosis trial data By Investing.com - Investing.com Australia
Pfizer-backed Priovant posts positive data for lead asset (PFE) - Seeking Alpha
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Priovant announces positive phase 2 results for brepocitinib in cutaneous sarcoidosis (Cs) - marketscreener.com
Roivant Sciences Ltd. SEC 10-Q Report - TradingView
Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 7c - StreetInsider
Roivant Sciences Swings to Fiscal Q3 Loss as Revenue Falls - marketscreener.com
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q3 Net Loss $0.38 a Share, vs. FactSet Est of $0.30 Loss - marketscreener.com
Roivant Sciences Ltd. Reports Positive Phase 2 Results and Financial Performance for Q3 2025 - TradingView
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 - The Manila Times
Roivant’s brepocitinib delivers rapid, sustained remissions in cutaneous sarcoidosis — first positive placebo-controlled trial - stocktitan.net
All eyes on Roivant earnings ahead of key drug trial readouts By Investing.com - Investing.com South Africa
All eyes on Roivant earnings ahead of key drug trial readouts - Investing.com Australia
Examining the Future: Roivant Sciences's Earnings Outlook - Benzinga
Understanding Momentum Shifts in (ROIV) - Stock Traders Daily
Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Increases By 25.3% - MarketBeat
Market Recap: Can Roivant Sciences Ltd sustain earnings growthJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Movement Recap: Whats the fair value of Roivant Sciences Ltd stockMarket Sentiment Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Roivant Sciences (ROIV) to Release Quarterly Earnings on Friday - MarketBeat
Is Roivant Sciences Ltd. benefiting from innovation trends2025 Retail Activity & Technical Buy Zone Confirmation - Mfd.ru
Revenue Check: Can Roivant Sciences Ltd generate free cash flowPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth - Seeking Alpha
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring the 19.57% Potential Upside in a High-Stakes Biotech Sector - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (ROIV) Movement - Stock Traders Daily
Y Intercept Hong Kong Ltd Buys 601,178 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - marketscreener.com
Parkside Financial Bank & Trust Has $10.57 Million Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Campbell & CO Investment Adviser LLC Sells 68,705 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Growth Value: Will GOOS benefit from geopolitical trendsInflation Watch & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - Sahm
Aug Summary: Can Roivant Sciences Ltd lead its sector in growthJuly 2025 Rallies & Low Risk Growth Stock Ideas - baoquankhu1.vn
Roivant Sciences Insider Sold Shares Worth $4,384,000, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences(ROIV.US) Officer Sells US$4.38 Million in Common Stock - 富途牛牛
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares - MarketBeat
Profit Review: What is the dividend yield of Roivant Sciences LtdMarket Trend Review & Low Risk Entry Point Guides - baoquankhu1.vn
Is Roivant Sciences Ltd forming a bullish divergenceJuly 2025 Technicals & Long-Term Growth Stock Strategies - baoquankhu1.vn
Roivant Sciences stock hits all-time high of $23.47 By Investing.com - Investing.com Nigeria
US Market Wrap: Does Roivant Sciences Ltd stock trade at a discount to peers2025 Technical Overview & Stepwise Entry and Exit Trade Signals - Bộ Nội Vụ
Roivant Sciences (NASDAQ:ROIV) Sets New 12-Month HighWhat's Next? - MarketBeat
0.23%
1.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):